Synthace is a Life Sciences R&D cloud platform that enables experiments to be automated, with the resultant data seamlessly integrated.
Sign up today and learn more about Synthace Stock
Invest in or value your shares in one or many pre-IPO companies through an EquityZen investment vehicle.
About Synthace Stock
Synthace is a R&D cloud platform. Synthace aims to automate experimentation and insight sharing for scientists to share, view, and access progress with cures and therapeutics in one place.
Synthace was founded in 2011 and is headquartered in London, White City. Notable investors include Horizons Ventures, Sofinnova Partners, Amadeus Capital Partners, and Luminous Ventures.
Co-founder & Chief Scientific Officer
Chief Product Officer
prnewswire - Dec, 7 2021IDBS and Synthace announce strategic partnership to streamline bioprocess data management
businesscloud - Nov, 17 2021Synthace raises £26m to automate drug development
finsmes - Nov, 16 2021Synthace Raises $35M in Series C Funding
ow - May, 20 2021Veteran Technology Executive Joins Synthace to Accelerate its Mission to Revolutionize the Life Science Research Market
zpr - Mar, 9 2021Synthace Appoints Dr. Nick Jurascheck as VP of Engineering
uktech - Nov, 5 2020Synthace and Ipsen Partner to Accelerate Novel Therapeutic Development Through Automation
sofinnovapartners - Jun, 11 2020Synthace and Tecan Announce Collaboration to Accelerate Purification Optimization in Process Development through Augmented Lab Automation
EquityZen does not have an affiliation with, formal relationship with, or endorsement from any companies featured above. This profile is based on publicly available information and is intended to be informative in nature.
Some data provided by Crunchbase